CA209-914

A Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants With Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse. Click here to learn more.

IPI-549-03

TITLE: A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of IPI-549 Administered in Combination with Front-line Treatment Regimens in Patients with Locally Advanced and/or Metastatic Triple-Negative Breast Cancer or Renal Cell Carcinoma. Click here to learn more.

Click here to learn more.


Learn more about Kidney Cancer >

Our Affiliations

 

 QCCA The Cancer FoundationNCI

We’re Here to Help! Click Below to Get Started